1. Dazucorilant, an experimental drug by Corcept Therapeutics, did not meet the main goal of slowing the decline in motor skills and functional criteria for ALS patients in a mid-stage trial. 2. Patients receiving dazucorilant experienced more gastrointestinal upset than those receiving the placebo. 3. No deaths were observed in the 300 mg dose group of dazucorilant, while five deaths were reported in the placebo group. 4. Complete study results will be presented next year. 5. An open-label, long-term extension study will continue, assessing overall survival in March 2025.
Listen Tab content
